Abstract
We conducted a cross-sectional analysis to assess the distribution of human papillomavirus (HPV) types and explored an acceptable strategy for cervical screening in Shenzhen, China. A total of 2717 individuals ranging in age from 30–59 years were recruited. Clinical sensitivity and specificity as well as positive (PPV) and negative (NPV) predictive values were estimated. A triage strategy was regarded as acceptable when the NPV was at least 98.0%. 432 (15.9%) participants presented HPV positive. The five most prevalent HPV types were HPV52 (22.9%), HPV16 (12.7%), HPV53 (10.0%), HPV51 (8.6%), and HPV58 (8.1%). The CIN2+ risks for each HPV type were 40.0% for HPV33, 32.4% for HPV16, 18.2% for HPV58, 13.3% for HPV56, and 11.1% for HPV68 in descending order. Baseline cytology testing combined with HPV16/33/52/58 genotyping met the NPV thresholds at 98.6% with a PPV of 17.9%, demonstrating excellent clinical performance for detecting HPV types in CIN2+ patients. In conclusion, triaging HPV-positive women by baseline cytology combined with HPV16/58/33/52 genotyping is an acceptable strategy for cervical cancer screening in Shenzhen, China.
Highlights
Human papillomavirus (HPV) infection is the primary risk factor for cervical cancer [1,2,3]
The sensitivity and specificity for detection of CIN2+ were 92.9% and 54.2%, respectively. This independent study evaluated the prevalence of human papillomavirus (HPV) genotypes in Shenzhen, a developed coastal city in China
A total of 15.9% of the study participants presented HPV positive, which was lower when compared to some western countries such as America, Italy, and Canada (18.1%-39.0%) [20,21,22,23], and higher than that in India and other regions of China (6.1%-12.9%) [20, 24]
Summary
Human papillomavirus (HPV) infection is the primary risk factor for cervical cancer [1,2,3]. Several longitudinal studies have demonstrated that being positive for high-risk types of HPV is a predictor of cervical intraepithelial neoplasia [4]. The results of several randomised clinical trials have demonstrated that the effectiveness of cervical cancer screening can be improved by detecting high-risk HPV DNA as a primary screening method for cervical cancer [5,6,7,8,9,10]. The information regarding the HPV prevalence and type distribution in a given population is necessary for the cancer prevention with prophylactic HPV vaccines and the development and evaluation of HPV screening tests
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
